June 23, 2017 2:23 PM ET


Company Overview of Targazyme, Inc.

Company Overview

Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...

3200 County Road 104

Floresville, TX 78114

United States

Founded in 2005



Key Executives for Targazyme, Inc.

Co-Founder, Chairman and Chief Executive Officer
Head of Operations and Vice President of CMC
Age: 50
Executive Director
Age: 61
Senior Vice President of Regulatory Affairs & Quality Assurance
Age: 73
Chief Business Officer
Compensation as of Fiscal Year 2016.

Targazyme, Inc. Key Developments

Targazyme, Inc. Receives FDA Clearance for Phase 2 Study of Pediatric Cancer Patients Undergoing Stem Cell Transplantation for Treatment of Hematologic Malignancies

Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in a Phase 2 clinical study to evaluate the efficacy of TZ101-fucosylated hematopoietic stem cell transplants in pediatric cancer patients.

Targazyme, Inc. Receives FDA Clearance for A Phase II Haplo-Identical Transplant Study of Patients Undergoing Bone Marrow Transplantation

Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in a Phase II clinical study to evaluate the safety and efficacy of TZ101-fucosylated bone marrow stem cells from haplo-identical donors in cancer patients. The transplantation of blood-forming stem cells from bone marrow is an accepted treatment to restore the body's ability to make blood and immune cells and is a treatment for various cancers like leukemia, lymphoma and some types of anemia. Recent medical advances have made possible the use of a haploidentical donor who is usually a 50% match to the recipient. Targazyme's product (TZ101) has the potential to improve the outcomes of this lifesaving treatment by improving the ability of TZ101 treated stem cells to home, adhere and engraft into the bone marrow, accelerating hematopoietic recovery, reducing both opportunistic infections and ICU/hospital stay for cancer patients undergoing the haplo-identical transplants.

Targazyme Enrolls First Patient in Phase 1/2 Study of TZ101 Fucosylated Regulatory T Cells

Targazyme, Inc. announced that it has enrolled the first patient in a Phase 1/2 TZ 101-treated regulatory T cell clinical study. This Phase 1/2 clinical study will evaluate the efficacy and safety of TZ101-treated regulatory T cells in the prevention and treatment of acute and chronic Graft-Versus-Host-Disease ("GVHD") in stem cell transplants. This clinical milestone will hopefully translate into the clinic the recent preclinical findings published in the journal Blood demonstrating the effectiveness of ex vivo treatment of regulatory T-cells with TZ101 in the prevention of GVHD.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Targazyme, Inc., please visit targazyme.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.